Proprietary Technology Solutions

Accelerate timelines with purpose-built solutions.

MMS is known for its solutions and therapeutic area expertise as a leading, data-focused CRO, but the secret to our success goes deeper. Internal leaders strive for more out of every project, and for us, that often means developing a strong tool, technology, or process. Their curiosity comes alive, as cross-functional teams explore new approaches through the likes of machine learning (ML), natural language processing (NLP), and artificial intelligence (AI).

To accelerate the expertise of our teams, MMS has and continues to develop several proprietary, purpose-built solutions to bring new levels of efficiency and savings to Sponsors.

We welcome you to explore our current technology offerings.

Suggested For You

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer